MOSCOW (Reuters) – Russia’s health ministry has given regulatory approval for the world’s first COVID-19 vaccine, developed by Moscow’s Gamaleya Institute, after less than two months of human testing, President Vladimir Putin said on Tuesday. The move paves the way for mass inoculation even as the final stages of clinical trials to test safety and […]
If you are not happy with the results below please do another search
50 search results for:
The U.S. death toll from Covid-19 fell 16% to about 7,200 people last week, the first decline in deaths after four weeks of increases, according to a Reuters tally of state and county reports.
The number of new Covid-19 cases among children in the United States rose 40% in the last two weeks of July, according to a report released just weeks before tens of millions of American students are scheduled to begin the new school year.
Global coronavirus cases pushed past 20 million, according to a Reuters tally, with the United States, Brazil and India accounting for more than half of all known infections.
Verastem signed a definitive deal to sell the company’s global commercial and development rights for Copiktra (duvelisib) to Secura Bio.
Convalescent therapy has been touted as a fast, effective response to Covid-19, but a new therapy by GigaGen Inc. could be even more promising.
Gilead Sciences Inc. filed a marketing application with the U.S. Food and Drug Administration for the company’s experimental Covid-19 drug remdesivir.
Omeros Corp.’s experimental treatment helped six patients with acute respiratory distress syndrome caused by Covid-19 recover and get discharged from the hospital, sending the drug developer’s shares up 60%.
In an aim to create a strong domestic supply chain, President Donald Trump signed an Executive Order that calls for federal agencies to purchase “essential drugs” and medical supplies that are produced in the United States, rather than from abroad as is the current practice.
Roche Holding’s experimental drug etrolizumab did not fare well in late-stage clinical trials in treating people with moderate to severe ulcerative colitis, the Swiss drugmaker said.